<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OPINION STATEMENT: The <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e> is a myelodsyplastic syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) characterized by symptomatic <z:hpo ids='HP_0001903'>anemia</z:hpo> and an indolent natural history with low transformation potential </plain></SENT>
<SENT sid="1" pm="."><plain>Our understanding of the molecular pathogenesis of this disease has advanced considerably, paralleled by the delineation of the relevant targets underlying selective lenalidomide sensitivity </plain></SENT>
<SENT sid="2" pm="."><plain>The context in which one treats the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e>, and <z:hpo ids='HP_0000001'>all</z:hpo> lower risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, is critical </plain></SENT>
<SENT sid="3" pm="."><plain>The focus of treatment should remain the amelioration of refractory cytopenias </plain></SENT>
<SENT sid="4" pm="."><plain>In the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e>, lenalidomide is the treatment of choice for patients with symptomatic <z:hpo ids='HP_0001903'>anemia</z:hpo> as it relieves the burden of transfusion dependence and <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in the majority of cases </plain></SENT>
<SENT sid="5" pm="."><plain>We discuss herein the current understanding of the biology of the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndrome</z:e>, actions of efficacy of lenalidomide and strategies for clinical management </plain></SENT>
</text></document>